Background: The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-term prophylaxis.
Objective: This analysis evaluated Berinert Patient Registry data regarding IV pnfC1-INH used as long-term prophylaxis (LTP).
Methods: The international registry (2010-2014) collected prospective and retrospective usage, dosing, and safety data on individuals who used pnfC1-INH for any reason.
Results: The registry included data on 47 subjects (80.9% female subjects; mean age, 44.8 years), which reflected 4082 infusions categorized as LTP and a total of 430.2 months of LTP administration. The median absolute dose of pnfC1-INH given for LTP was 1000 IU (range, 500-3000 IU), with a median time interval between infusion and a subsequent pnfC1-INH-treated attack of 72.0 hours (range, 0.0-166.4 hours). Fifteen subjects (31.9%) had no pnfC1-INH-treated HAE attacks within 7 days after pnfC1-INH infusion for LTP; 32 subjects (68.1%) experienced 246 attacks, with rates of 0.06 attacks per infusion and 0.57 attacks per month. A total of 81 adverse events were reported in 16 subjects (34.0%) (0.02 events per infusion; 0.19 events per month); only 3 adverse events were considered related to pnfC1-INH (noncardiac chest pain, postinfusion headache, deep vein thrombosis in a subject with an IV port).
Conclusion: In this international registry, IV pnf-C1-INH given as LTP for HAE was safe and efficacious, with a low rate of attacks that required pnfC1-INH treatment, particularly within the first several days after LTP administration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380447 | PMC |
| http://dx.doi.org/10.2500/ar.2017.8.0192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pregnancy revealing hereditary angioedema type III with factor XII mutation managed in a resource-limited setting with no C1-inhibitor concentrate availability: a case report.
Int J Obstet Anesth
October 2024
Department of Dermatology, Venerology and Allergology, CHU Mohammed VI, Oujda, Morocco; Laboratory of Epidemiology, Clinical Research and Public Health. Faculty of Medicine and Pharmacy, Mohammed Premier University, Oujda, Morocco.
Hereditary angioedema (HAE) in children and adolescents: New treatment options.
Allergol Select
October 2024
Hannover Medical School (MHH), Department of Dermatology, Allergology and Venereology, Interdisciplinary Allergy Center of the MHH, Treatment Center for Hereditary Angioedema of the MHH, Hannover, Germany.
Article Synopsis
- Modern management of hereditary angioedema (HAE) emphasizes personalized treatment plans tailored to the needs of children and adolescents, as well as the severity of the disease.
- New medications have improved quality of life for HAE patients, but not all are approved for children, leading to ongoing research into alternative treatments such as those targeting bradykinin effects.
- Emerging options like oral medications, long-acting therapies, and potential gene therapy are being explored to better meet the care requirements for young patients with HAE type I and II.
Association of Endothelial Cell Activation with Acute Kidney Injury during Coronary Angiography and the Influence of Recombinant Human C1 Inhibitor-A Secondary Analysis of a Randomized, Placebo-Controlled, Double-Blind Trial.
Biomedicines
August 2024
Division of Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland.
Background: Acute kidney injury (AKI) as a result of iodinated contrast media (CM) has been linked to CM-induced renal ischemia and toxic effects on endothelial cells (EC). The recombinant human C1 inhibitor (rhC1INH) has been shown to influence EC activation.
Methods: Secondary analysis of 74/77 (96%) participants of a double-blind, randomized, and placebo-controlled study that assessed the effect of rhC1INH on AKI.
Uncovering a novel SERPING1 pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema.
Orphanet J Rare Dis
September 2024
Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32 The First Ring Road West 2, Chengdu, Sichuan, 610072, China.
Article Synopsis
- Hereditary angioedema (HAE) is a rare genetic condition that causes recurrent swelling and can be life-threatening, with limited ways to predict or prevent attacks.
- A novel mutation in the SERPING1 gene was found in a Han family with HAE, leading to cellular dysfunction due to increased C1-INH levels and subsequent mitochondrial damage.
- Monitoring intracellular calcium levels may provide a new method for predicting HAE attacks, which could improve management strategies for the condition.
[Two pediatric hereditary angioedemathe families: case report and literature review].
Zhonghua Er Ke Za Zhi
September 2024
Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Article Synopsis
- The study looks at two families with a condition called hereditary angioedema, which causes swelling in different body parts, especially in children.
- One girl, age 12, had ongoing stomach pain and was found to have a genetic change related to her condition, while another girl, age 17, had swelling in her limbs and was also diagnosed with a different type of hereditary angioedema.
- Researchers reviewed a lot of information about this condition in kids and found that it can be inherited and often starts showing symptoms between ages 1 and 15.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!